Proactive Investors - Run By Investors For Investors

Merck's 2Q earnings beat Street with sales turbocharged by cancer drug Keytruda

Drug giant raised its full-year guidance to a range of US$4.22 and US$4.30 a share compared with US$4.16 to US$4.28 a share expected last quarter
Merck billboard
Sales of Merck’s cancer drug Keytruda increased 89% to $1.67bn during the quarter

Merck & Co. Inc (NYSE:MRK) reported second quarter earnings Friday that topped Wall Street estimates on strong sales of its cancer drug Keytruda which is battling with rival Bristol-Myers Squibb Co’s (NYSE:BMY) blockbuster cancer drug Opdivo.

The pharmaceutical giant reported earnings of US$1.06 per share on revenue of US$10.5bn. It handily beat consensus earnings estimates of US$1.03 per share on revenue of US$10.4bn. Revenue grew 5.4% on a year-over-year basis.

All eyes were on sales of Merck’s cancer drug Keytruda which increased 89% to $1.67bn during the quarter compared with US$881mln a year ago.

READ: Bristol-Myers Squibb's 2Q earnings beat Street on healthy sales of its blockbuster cancer drug Opdivo

Shares in Merck traded flat, slightly down to US$63.84 in premarket trade.

“Strong commercial execution globally for Keytruda, Gardasil, Bridion and other products led the company to deliver growth in the second quarter,” said Merck CEO Kenneth C. Frazier. “We continue to solidify our leadership in immuno-oncology and, along with our other key pillars of growth including Animal Health, we are confident in the strength of our business.”

The company said its research and development expenses increased 28% to US$2.3bn. Most of the increases came from a charge of US$344mln related to the acquisition of Australian biotechnology company Viralytics Ltd.

The company said it expects 2018 earnings of US$4.22 to US$4.30 per share on revenue of US$42bn to US$42.8bn. The company's previous guidance was earnings of US$4.16 to US$4.28 per share on revenue of US$41.8bn to US$43bn. The current consensus earnings estimate is a more conservative US$4.22 per share on revenue of US$42.17bn for the year ending December 31, 2018.

Contact Uttara Choudhury at [email protected]
Follow her on Twitter: @UttaraProactive

View full MRK profile View Profile

Merck & Co Timeline

Related Articles

Vial of pills
June 25 2018
Cosmos is a modern company, but the trade routes it relies on are ancient
scientist in lab
August 31 2018
While the data bodes well for MTD201, Midatech is most excited by the validation of its Q-Sphera sustained release technology, which it is using in some of its other compounds
Cancer cells
June 27 2018
The Nottingham-based privately-owned company has made an impressive fist of developing the OMIS (Opto-magnetic Imaging Spectroscopy) cancer detection system

© Proactive Investors 2018

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use